Protocols

Three scientists share Nobel for pioneering work on phage display and enzymes; Kite antes up $10M in TCR discovery deal

Frances Arnold from the California Institute of Technology will share this year’s Nobel prize for chemistry. Her work on the “directed evolution” of enzymes offered a new approach to bespoke catalysts for new chemical reactions, setting up an advance that has played a role in pharmaceuticals as well as renewable energy. She is being recognized alongside George Smith and Sir Gregory Winter, who played a pioneering role in phage display, which has had a major impact on the development of antibodies.

→ Looking for a follow-on to its groundbreaking CAR-T therapy, Kite Pharma has signed on the cell screening experts at HiFiBiO Therapeutics to take a deep look into neoantigen-reactive T cell receptors. The Gilead subsidiary is paying $10 million for access and a right to license HiFiBiO’s tech platform, which has capacity for “in-depth screening of TCR repertoires from patient samples to identify shared antigen and neoantigen TCRs for use in adoptive cellular therapies.”

Twist Bioscience, a manufacturer and supplier of synthetic DNA, is seeking an $86 million IPO. Other than updating the platform and expanding its sales operations — which currently boasts of 600 biopharma, ag and tech clients — the San Francisco-based company also plans to spend its proceeds on a manufacturing site in China.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 37,500+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Biotech Investment Analyst
SV Health Investors Boston, MA
Director, Program Management
Contrafect Corporation New York, NY
Director, Translational Sciences
Cadent Therapeutics Cambridge, MA

Visit Endpoints Careers ->